Literature DB >> 8973032

Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan.

K Nishioka1, I Katayama, H Kondo, H Shinkai, H Ueki, K Tamaki, K Takehara, S Tajima, M Maeda, S Hayashi, H Kodama, Y Miyachi, H Mizutani, A Fujisaku, T Sasaki, M Shimizu, J Kaburagi.   

Abstract

For the first time, we performed an epidemiological study of SSc in Japan to study the factors influencing prognosis, survival rate and cause of death of Japanese SSc patients and to compare our data with those from foreign countries. Prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc) was analyzed based on clinical data described in case cards provided by the members of the Scleroderma Research Committee of the Japanese Ministry of Health and Welfare. The essential observation period was from 5 to 20 years, at ending in 1994. Ninety patients died (males 11, females 79). The age of onset of the deceased patients was significantly higher than that of surviving patients (deceased, 45.6 yrs, surviving 41.3 yrs). Statistically significant factors for a poor prognosis were as follows: Barnett type III > type II > type I, positive for anti-Scl-70 antibody, negative for anti-centromere antibody. The survival rate at 5 years after the onset of the disease was 0.937, followed by 0.82 at 10 years, 0.567 at 20 years and 0.40 at 30 years after the onset. Sex was not a predictor for prognosis, although male patients died at an earlier stage of the disease. The most common causes of death were heart failure, pulmonary insufficiency, lung fibrosis, and renal failure. Twenty-four patients had cancer of which 13 were lung cancers. The current status of the survival rate and prognostic factors of 496 Japanese SSc patients is summarized. In future, more well-controlled studies using the same criteria should be performed for the better understanding and management of SSc.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973032     DOI: 10.1111/j.1346-8138.1996.tb02680.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  14 in total

1.  Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease?

Authors:  Ramya Janardana; Aswin M Nair; Ajit K Surin; John Anthony Jude Prakash; Mahasampath Gowri; Debashish Danda
Journal:  Clin Rheumatol       Date:  2019-07-15       Impact factor: 2.980

Review 2.  Periostin in the pathogenesis of skin diseases.

Authors:  Hiroyuki Murota; Yang Lingli; Ichiro Katayama
Journal:  Cell Mol Life Sci       Date:  2017-09-15       Impact factor: 9.261

3.  Systemic Sclerosis and Pulmonary Disease.

Authors:  Khoa Ngo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey.

Authors:  Ferit Zuhur; Sayid Shafi Zuhur; Cigdem Zuhur; Benan Musellim; Gul Ongen
Journal:  Rheumatol Int       Date:  2011-03-05       Impact factor: 2.631

5.  Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele.

Authors:  P G Vlachoyiannopoulos; U G Dafni; I Pakas; M Spyropoulou-Vlachou; C Stavropoulos-Giokas; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

6.  The prognostic factors of systemic sclerosis for survival among Koreans.

Authors:  Jinhyun Kim; Sue Kyung Park; Ki Won Moon; Eun Young Lee; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Clin Rheumatol       Date:  2009-12-03       Impact factor: 2.980

7.  Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis.

Authors:  Robyn T Domsic; Svetlana I Nihtyanova; Stephen R Wisniewski; Michael J Fine; Mary Lucas; C Kent Kwoh; Christopher P Denton; Thomas A Medsger
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

Review 8.  Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations.

Authors:  John D Reveille
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

9.  Identification of myocardial damage in systemic sclerosis: a nuclear cardiology approach.

Authors:  Kenichi Nakajima; Shinro Matsuo; Minoru Hasegawa; Seigo Kinuya; Kazuhiko Takehara
Journal:  Int J Rheumatol       Date:  2010-08-31

Review 10.  Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment.

Authors:  Shirin Assar; Hosna Khazaei; Maryam Naseri; Fardous El-Senduny; Saeideh Momtaz; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  J Immunol Res       Date:  2021-06-24       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.